Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global Complicated Urinary Tract Infections treatment market size is expected to surpass an impressive valuation of USD 9.2 billion in 2023 and is projected to reach USD 16.1 billion by 2033, trailing a CAGR of 5.76%
Due to the increase in drug-resistant bacteria and overuse of antibiotics, the prevalence of complicated urinary tract infections is expected to grow in the future which will fuel the market expansion of complicated urinary tract infection treatment. The increasing prescription of quinolones by doctors to treat complex UTI situations will propel market growth. Also, the use of Cephalosporin as a secondary treatment option will also aid in the market growth.
However, conflicting guidelines on complicated urinary tract infections issued by several organizations cause confusion among providers that will negatively impact the growth of the complicated urinary tract infection treatment market.
Report Attribute | Details |
---|---|
Expected Market Value (2023) | US$ 9.2 billion |
Anticipated Forecast Value (2033) | US$ 16.1 billion |
Projected Growth Rate (2023 to 2033) | CAGR 5.76% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for complicated urinary tract infection treatment was worth USD 7.6 billion in 2018 while growing at a CAGR of 3.9% during the historical period.
The high demand for antibiotics as they are the only treatment for complicated urinary tract infections and urinary tract infections will transform the market scenario.
There is currently no approved drug for oral use, so the first-ever FDA approval for oral drugs will provide a competitive advantage in the complicated urinary tract infections market which will open up new avenues for the market. Furthermore, increasing mergers, acquisitions, and collaborations between companies to develop safe and effective drugs will drive the complicated urinary tract infections market growth.
Also, for treating complicated urinary tract infections, fluoroquinolones such as ciprofloxacin or ofloxacin are prescribed in case of less severe infection. Apart from these, the loss of patent rights of branded drugs and the availability of cost-effective antibiotics from generic companies are among the factors that are likely to spur the growth of the complicated urinary tract infection treatment market.
After a comprehensive analysis of the above-mentioned factors, the market for complicated Urinary tract infections treatment market is projected to reach USD 16.1 billion by 2033 with a CAGR of 5.76% during the forecast period.
The arrival of pipeline therapies to drive market growth
The complicated urinary tract infections therapies in the pipeline include Tebipenem Pivoxil Hydrobromide (SPR994), Cefepime-zidebactam (WCK-5222), Cefepime/Taniborbactam, Cefepime/Enmetazobactam, Fosfomycin (ZT-01/Contempo), Finafloxacin, and others. These therapies are expected to augment the growth of the Complicated urinary tract infections treatment market during the forecast period.
The growth in complicated urinary tract infections market size is also a direct consequence of a rise in research and development activity, a growing prevalent population, and the expected commercial success of upcoming therapies.
With increasing multidrug resistance and antibiotic overuse, the prevalence of complicated urinary tract infections is anticipated to rise in the future, leading to the growth of the complicated urinary tract infections market. Furthermore, research and development of novel classes of antibiotics for complicated UTIs are expected to aid the complicated urinary tract infections market growth.
High cost and potential side effects to restrain market expansion
Inadequate treatment of complicated urinary tract infections increases healthcare costs, exposes patients to potential side effects, and increases antibiotic resistance, thus restraining the growth of the complicated urinary tract infections market. Moreover, variability in study participants, a small sample size, a lack of blinding or placebo control, unpredictability in follow-up, and the exclusion of patients with resistant isolates are all likely to hinder clinical trial study evaluation in the complicated urinary tract infections market.
As the clinical trial of an antibiotic differs from other therapeutic drugs in terms of clinical approval approach, such as clinical trial design, interpretation, and analysis; complex regulatory requirements are anticipated to hamper the growth of the complicated urinary tract infections market.
North America to lead the market with the maximum share
The Complicated urinary tract infections treatment market in this region is estimated to grow USD 5.29 billion by 2033, exhibiting a CAGR of 4% during the forecast period. It is estimated to hold a 32.9% industry share by end of the projected period. The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for complicated urinary tract infections which will fuel growth in this region.
Additionally, according to a study published in Therapeutic Advances in Urology in May 2020 titled An Introduction to the Epidemiology and Burden of Urinary Tract Infections, urinary tract infections (UTIs) are the most common outpatient infections in adult women, with a lifetime prevalence of 50-60%. Urinary tract infections are a substantial societal and personal burden, with complicated urinary tract infections accounting for a significant number of medical visits in the US each year. This condition is estimated to drive the market by increasing sales of urinary tract infection medicines in the region.
On the other hand, research, and development of novel classes of antibiotics for urinary tract infections are anticipated to aid in market expansion. In August 2020, for example, researchers at California Polytechnic State University announced the development of a new class of antibiotics for urinary tract infections that target bacterial iron acquisition.
Thus, all the above factors are expected to propel growth in the region during the forecast period.
East Asia propelling growth at fastest CAGR
The market in East Asia is projected to be worth USD 3.2 billion by 2033 while growing at a CAGR of 5.1% during the forecast period. This region is estimated to account for around 20% market share by end of the forecast period. The growth is attributable to high investments in research and development departments by key players to combine and launch new medications that are tailored to the needs of the East-Asian market. Growth in the prevalence of hospital-acquired UTIs and technological advancements in testing instruments will drive growth. Furthermore, excellent reimbursement conditions and illness management will boost market expansion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Penicillin and combinations to reflect growth with the fastest CAGR
The penicillin and Combinations Segment is projected to grow with the fastest compounded annual growth rate of 7.9% during the forecast period. The growth is attributed to the rising prevalence of urinary tract infections (UTIs). Most penicillin’s widely being used directly and in combinations for treating urinary tract infections that are augmenting the segment’s growth.
Quinolones fuelling segments growth with maximum share
This segment is estimated to hold around 48.6% market share by end of the forecast period. The growth is attributed to the surge in demand for novel UTI therapeutics. Quinolones represent a natural alternative to trimethoprim-sulfamethoxazole for treating urinary tract infections (UTIs) when resistance becomes a potential problem. Quinolones are broadly active against most Gram-negative and Gram-positive organisms, so that multi-drug resistance is avoided in the treatment of urinary tract infections. Thus, driving the segment’s growth.
Also, these drugs have the capability to improve quality of life and combat symptoms with high therapeutic effects. These lifesaving advantages of quinolones make them the most profitable and highly adopted products across regions that fuel the growth of the overall market.
Hospital pharmacies lead the segment with dominating share
This segment is estimated to dominate the market with a maximum market share of 51% by end of the forecast period. The growth is attributable to high investments in hospital infrastructure and faster adoption of various novel drugs for the treatment of complicated urinary tract infections.
The global Complicated Urinary Tract Infections treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals, Allegra Therapeutics, Nabriva Therapeutics AG, MerLion Pharmaceuticals, Allergan, Bayer AG, Pfizer, Inc, GlaxoSmithKline plc, Bristol-Myers Squibb Company, Janssen Global Services, LLC
Some recent developments in this industry are:
Report Attribute | Details |
---|---|
Market Value in 2023 | US$ 9.2 billion |
Market Value in 2033 | US$ 16.1 billion |
Growth Rate | CAGR of 5.76% from 2023 to 2033 |
Base Year for Estimation | 2022 |
Historical Data | 2018 to 2022 |
Forecast Period | 2023 to 2033 |
Quantitative Units | Revenue in USD billion and CAGR from 2023 to 2033 |
Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
Segments Covered |
|
Regions Covered |
|
Key Countries Profiled |
|
Key Companies Profiled |
|
Customization | Available Upon Request |
The rising need for innovative antibiotics, and expanded healthcare infrastructure are some important potentials.
Increase in the occurrence of infections that are resistant to treatment and the need for shorter treatment times.
Due to their proven efficacy, antibiotics continue to be a prominent sector.
The creation of non-antibiotic substitutes and use of artificial intelligence in medication research are recent trends.
Increased R&D investments and collaborations are being driven by market dynamics.
1. Executive Summary | Complicated Urinary Tract Infections Treatment Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Penicillin and Combinations 5.3.2. Quinolones 5.3.3. Cephalosporin 5.3.4. Azoles and Amphotericin B 5.3.5. Nitro furans 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 6.3.1. Hospital Pharmacies 6.3.2. Gynaecology and Urology Clinics 6.3.3. Drug Stores 6.3.4. Retail Pharmacies 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. MIDDLE EAST AND AFRICA 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. United States of America 8.2.1.2. Canada 8.2.2. By Drug Class 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Drug Class 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Drug Class 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. United Kingdom 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Drug Class 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Drug Class 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Drug Class 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Drug Class 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. MIDDLE EAST AND AFRICA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MIDDLE EAST AND AFRICA 14.2.2. By Drug Class 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. United States of America 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Drug Class 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Drug Class 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Drug Class 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Drug Class 15.4.2.2. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Drug Class 15.5.2.2. By Distribution Channel 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Drug Class 15.6.2.2. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Drug Class 15.7.2.2. By Distribution Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Drug Class 15.8.2.2. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Drug Class 15.9.2.2. By Distribution Channel 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Drug Class 15.10.2.2. By Distribution Channel 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Drug Class 15.11.2.2. By Distribution Channel 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Drug Class 15.12.2.2. By Distribution Channel 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Drug Class 15.13.2.2. By Distribution Channel 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Drug Class 15.14.2.2. By Distribution Channel 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Drug Class 15.15.2.2. By Distribution Channel 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Drug Class 15.16.2.2. By Distribution Channel 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Drug Class 15.17.2.2. By Distribution Channel 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Drug Class 15.18.2.2. By Distribution Channel 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Drug Class 15.19.2.2. By Distribution Channel 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Drug Class 15.20.2.2. By Distribution Channel 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Drug Class 15.21.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Drug Class 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Spero Therapeutics 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Wockhardt 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Venatorx Pharmaceuticals 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Allecra Therapeutics 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Nabriva Therapeutics AG 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. MerLion Pharmaceuticals 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Allergan 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Bayer AG 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Pfizer, Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. GlaxoSmithKline plc 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. Bristol-Myers Squibb Company 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.12. Janssen Global Services, LLC 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 11: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 17: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 20: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033 Table 22: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 23: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 24: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 15: Global Market Attractiveness by Region, 2023 to 2033 Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 30: North America Market Attractiveness by Country, 2023 to 2033 Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 46: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 52: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 60: Europe Market Attractiveness by Country, 2023 to 2033 Figure 61: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 67: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 68: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 73: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 76: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 82: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 88: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 91: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 97: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 98: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 103: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 106: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 107: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Distribution Channel, 2023 to 2033 Figure 108: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033 Figure 109: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 110: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 111: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 112: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 113: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 114: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 115: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033 Figure 116: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033 Figure 117: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033 Figure 118: MIDDLE EAST AND AFRICA Market Attractiveness by Drug Class, 2023 to 2033 Figure 119: MIDDLE EAST AND AFRICA Market Attractiveness by Distribution Channel, 2023 to 2033 Figure 120: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033
Recommendations
Healthcare
Published : June 2023
Explore Healthcare Insights
View Reports